Literature DB >> 4038335

2-Chloroadenosine, a permeant for the nucleoside transporter.

S M Jarvis, B W Martin, A S Ng.   

Abstract

Human erythrocytes were shown to possess a saturable uptake mechanism for 2-chloroadenosine (apparent Km 23 microM, 22 degrees). Uptake by this route was inhibited by nitrobenzylthioinosine, uridine and adenosine, but adenine had no effect. In addition, uridine caused the countertransport of 2-chloroadenosine and vice versa. 2-Chloroadenosine was also shown to be an apparent competitive inhibitor of uridine influx (apparent Ki value of 33 microM) and high-affinity nitrobenzylthioinosine binding (apparent Ki 0.18 mM). The apparent Ki value for inhibition of uridine influx was close to the apparent Km value for 2-chloroadenosine uptake. Previous studies [Jarvis et al., Biochem. J. 208, 83 (1982)] have demonstrated that dog erythrocytes do not possess a saturable transport system for uridine and adenosine. Similarly, in the present study, the entry of 2-chloroadenosine into dog erythrocytes was slow and linear with concentration. Nitrobenzylthioinosine (NBMPR) had no effect on the uptake of 2-chloroadenosine into dog erythrocytes. These results demonstrate that 2-chloroadenosine enters human erythrocytes by the same nucleoside carrier as other nucleosides. It is suggested from these data that the previous explanation that the inability of nucleoside transport inhibitors to potentiate the pharmacological effects of 2-chloroadenosine was due to the failure of the nucleoside carrier to accept 2-chloroadenosine as a permeant may have to be reassessed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038335     DOI: 10.1016/0006-2952(85)90340-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Adenosine deaminase and adenosine uptake inhibitions facilitate ventilation in rats.

Authors:  E C Monteiro; J A Ribeiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-08       Impact factor: 3.000

2.  On the role, inactivation and origin of endogenous adenosine at the frog neuromuscular junction.

Authors:  J A Ribeiro; A M Sebastião
Journal:  J Physiol       Date:  1987-03       Impact factor: 5.182

3.  2-Chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling.

Authors:  Masahiro Koshiba; Hidekazu Kosaka; Takashi Nakazawa; Nobuhide Hayashi; Ryuichi Saura; Noriko Kitamura; Shunichi Kumagai
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Inhibition by nucleosides of glucose-transport activity in human erythrocytes.

Authors:  S M Jarvis
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

5.  Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2.

Authors:  Meaghan Stolk; Elizabeth Cooper; Greg Vilk; David W Litchfield; James R Hammond
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

6.  Interactions between adenosine and phorbol esters or lithium at the frog neuromuscular junction.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

7.  Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria.

Authors:  M G Collis; K A Jacobson; D M Tomkins
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

8.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  Trans-stimulation and trans-inhibition of uridine efflux from human erythrocytes by permeant nucleosides.

Authors:  S M Jarvis
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

10.  On the adenosine receptor and adenosine inactivation at the rat diaphragm neuromuscular junction.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.